Morphogens and blood-brain barrier function in health and disease

Tissue Barriers

Volumn 4, Issue 1, 2016, Pages

  Wevers, Nienke R ^a   de Vries, Helga E ^b  

^a MIMETAS BV   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

blood brain barrier; brain diseases; morphogens; neurogenesis; neurovascular unit

Indexed keywords

ABC TRANSPORTER; ANGIOPOIETIN; BETA CATENIN; CD31 ANTIGEN; CLAUDIN 3; GLUCOSE TRANSPORTER 1; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; MORPHOGEN; MULTIDRUG RESISTANCE PROTEIN; P SELECTIN GLYCOPROTEIN LIGAND 1; RETINOIC ACID; SEMAPHORIN; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN FUNCTION; BRAIN PERICYTE; CELL MEMBRANE PERMEABILITY; DISEASE SEVERITY; DNA DAMAGE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MICROVASCULATURE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; TIGHT JUNCTION; ANIMAL; CYTOLOGY; DEGENERATIVE DISEASE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84981210875     PISSN: 21688362     EISSN: 21688370     Source Type: Journal    
DOI: 10.1080/21688370.2015.1090524     Document Type: Article

References (153)

1. S.Shen, W.Zhang. ABC transporters and drug efflux at the blood-brain barrier. Rev. Neurosci. 2010; 21(1):29-53; PMID:20458886
2. R.Spector. Nutrient transport systems in brain: 40 years of progress. J. Neurochem. 2009; 111(2):315-20; PMID:19686385; http://dx.doi.org/10.1111/j.1471-4159.2009.06326.x
3. H.Wolburg, A.Lippoldt. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 2002; 38(6):323-37; PMID:12529927; http://dx.doi.org/10.1016/S1537-1891(02)00200-8
4. N.J.Abbott, L.Rönnbäck, E.Hansson. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006; 7(1):41-53; PMID:16371949; http://dx.doi.org/10.1038/nrn1824
5. G.S.Duncan, D.P.Andrew, H.Takimoto, S.A.Kaufman, H.Yoshida, J.Spellberg, J.L.de la Pompa, A.Elia, A.Wakeham, B.Karan-Tamir, et al. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J. Immunol. 1999; 162(5):3022-30; PMID:10072554
6. W.-Y.Liu, Z.-B.Wang, L.-C.Zhang, X.Wei, L.Li. Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci. Ther. 2012; 18(8):609-15; PMID:22686334; http://dx.doi.org/10.1111/j.1755-5949.2012.00340.x
7. S.Tietz, B.Engelhardt. Brain barriers: Crosstalk between complex tight junctions and adherens junctions. J. Cell Biol. 2015; 209(4):493-506; PMID:26008742; http://dx.doi.org/10.1083/jcb.201412147
8. I.Sá-Pereira, D.Brites, M.A.Brito. Neurovascular unit: a focus on pericytes. Mol. Neurobiol. 2012; 45(2):327-47; http://dx.doi.org/10.1007/s12035-012-8244-2
9. R.Daneman. The blood-brain barrier in health and disease. Ann. Neurol. 2012; 72(5):648-72; PMID:23280789; http://dx.doi.org/10.1002/ana.23648
10. B.Engelhardt. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J. Neurol. Sci. 2008; 274(1-2):23-6; PMID:18573502; http://dx.doi.org/10.1016/j.jns.2008.05.019
11. B.Engelhardt, R.M.Ransohoff. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012; 33(12):579-89; PMID:22926201; http://dx.doi.org/10.1016/j.it.2012.07.004
12. H.E.De Vries, M.C.M.Blom-Roosemalen, M.V.OostenM van, A.G.de Boer, T.J.van Berkel, D.D.Breimer, J.Kuiper. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J. Neuroimmunol. 1996; 64(1):37-43; PMID:8598388; http://dx.doi.org/10.1016/0165-5728(95)00148-4
13. M.Juhler, R.G.Blasberg, J.D.Fenstermacher, C.S.Patlak, O.B.Paulson. A spatial analysis of the blood-brain barrier damage in experimental allergic encephalomyelitis. J. Cereb. Blood Flow Metab. 1985; 5(4):545-53; PMID:3877064; http://dx.doi.org/10.1038/jcbfm.1985.82
14. D.-H.Lee, R.Gold, R.A.Linker. Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. Int. J. Mol. Sci. 2012; 13(9):11783-803; PMID:23109883; http://dx.doi.org/10.3390/ijms130911783
15. C.Griot, M.Vandevelde, A.Richard, E.Peterhans, R.Stocker. Selective degeneration of oligodendrocytes mediated by reactive oxygen species. Free Radic. Res. Commun. 1990; 11(4–5):181-93; PMID:1965721; http://dx.doi.org/10.3109/10715769009088915
16. S.E.Lakhan, A.Kirchgessner, D.Tepper, A.Leonard. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 2013; 4:32; PMID:23565108
17. H.Lassmann, J.van Horssen, D.Mahad. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012; 8(11):647-56; PMID:23007702; http://dx.doi.org/10.1038/nrneurol.2012.168
18. M.C.Carreiras, E.Mendes, M.J.Perry, A.P.Francisco, J.Marco-Contelles. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem. 2013; 13(15):1745-70; PMID:23931435; http://dx.doi.org/10.2174/15680266113139990135
19. Y.Ozawa. Neurodegenerative disease: Pieces of the Parkinson's puzzle. Nat. Rev. Neurosci. 2010; 11(12):787-787; PMID:21132875; http://dx.doi.org/10.1038/nrn2945
20. O.Hardiman, L.H.van den Berg, M.C.Kiernan. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011; 7(11):639-49; PMID:21989247; http://dx.doi.org/10.1038/nrneurol.2011.153
21. H.L.Ashe, J.Briscoe. The interpretation of morphogen gradients. Development 2006; 133(3):385-94; PMID:16410409; http://dx.doi.org/10.1242/dev.02238
22. T.Østerlund, P.Kogerman. Hedgehog signalling: how to get from Smo to Ci and Gli. Trends Cell Biol. 2006; 16(4):176-80; http://dx.doi.org/10.1016/j.tcb.2006.02.004
23. I.Patten, M.Placzek. The role of Sonic hedgehog in neural tube patterning. Cell. Mol. Life Sci. 2000; 57(12):1695-708; PMID:11130176; http://dx.doi.org/10.1007/PL00000652
24. F.Charron, E.Stein, J.Jeong, A.P.McMahon, M.Tessier-Lavigne. The Morphogen Sonic Hedgehog Is an Axonal Chemoattractant that Collaborates with Netrin-1 in Midline Axon Guidance. Cell 2003; 113(1):11-23; PMID:12679031; http://dx.doi.org/10.1016/S0092-8674(03)00199-5
25. J.I.Alvarez, A.Dodelet-Devillers, H.Kebir, I.Ifergan, P.J.Fabre, S.Terouz, M.Sabbagh, K.Wosik, L.Bourbonnière, M.Bernard, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011; 334(6063):1727-31; PMID:22144466; http://dx.doi.org/10.1126/science.1206936
26. Y.Wang, S.Jin, Y.Sonobe, Y.Cheng, H.Horiuchi, B.Parajuli, J.Kawanokuchi, T.Mizuno, H.Takeuchi, A.Suzumura. Interleukin-1β induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. Kira J, ed. PLoS One 2014; 9(10):e110024; PMID:25313834; http://dx.doi.org/10.1371/journal.pone.0110024
27. N.M.Amankulor, D.Hambardzumyan, S.M.Pyonteck, O.J.Becher, J.A.Joyce, E.C.Holland. Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J. Neurosci. 2009; 29(33):10299-308; PMID:19692604; http://dx.doi.org/10.1523/JNEUROSCI.2500-09.2009
28. Q.G.Xu, R.Midha, J.A.Martinez, G.F.Guo, D.W.Zochodne. Facilitated sprouting in a peripheral nerve injury. Neuroscience 2008; 152(4):877-87; PMID:18358630; http://dx.doi.org/10.1016/j.neuroscience.2008.01.060
29. F.G.Mastronardi, L.A.G.daCruz, H.Wang, J.Boggs, M.A.Moscarello. The amount of sonic hedgehog in multiple sclerosis white matter is decreased and cleavage to the signaling peptide is deficient. Mult. Scler. 2003; 9(4):362-71; PMID:12926841; http://dx.doi.org/10.1191/1352458503ms924oa
30. Y.Zhang, W.Dong, S.Guo, S.Zhao, S.He, L.Zhang, Y.Tang, H.Wang. Lentivirus-mediated delivery of sonic hedgehog into the striatum stimulates neuroregeneration in a rat model of Parkinson disease. Neurol. Sci. 2014; 35(12):1931-40; PMID:25030123; http://dx.doi.org/10.1007/s10072-014-1866-6
31. C.Liu, Y.Li, M.Semenov, C.Han, G.H.Baeg, Y.Tan, Z.Zhang, X.Lin, X.He. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108(6):837-47; PMID:11955436; http://dx.doi.org/10.1016/S0092-8674(02)00685-2
32. T.Maniatis. A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 1999; 13(5):505-10; PMID:10072378; http://dx.doi.org/10.1101/gad.13.5.505
33. M.Buscarlet, S.Stifani. The “Marx” of Groucho on development and disease. Trends Cell Biol. 2007; 17(7):353-61; PMID:17643306; http://dx.doi.org/10.1016/j.tcb.2007.07.002
34. M.Joksimovic, M.Patel, M.M.Taketo, R.Johnson, R.Awatramani. Ectopic Wnt/beta-catenin signaling induces neurogenesis in the spinal cord and hindbrain floor plate. PLoS One 2012; 7(1):e30266; PMID:22276170; http://dx.doi.org/10.1371/journal.pone.0030266
35. M.Tang, J.C.Villaescusa, S.X.Luo, C.Guitarte, S.Lei, Y.Miyamoto, M.M.Taketo, E.Arenas, E.J.Huang. Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J. Neurosci. 2010; 30(27):9280-91; PMID:20610763; http://dx.doi.org/10.1523/JNEUROSCI.0860-10.2010
36. A.A.Gulacsi, S.A.Anderson. Beta-catenin-mediated Wnt signaling regulates neurogenesis in the ventral telencephalon. Nat. Neurosci. 2008; 11(12):1383-91; PMID:18997789; http://dx.doi.org/10.1038/nn.2226
37. R.Daneman, D.Agalliu, L.Zhou, F.Kuhnert, C.J.Kuo, B.A.Barres. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009; 106(2):641-6; PMID:19129494; http://dx.doi.org/10.1073/pnas.0805165106
38. S.Liebner, M.Corada, T.Bangsow, J.Babbage, A.Taddei, C.J.Czupalla, M.Reis, A.Felici, H.Wolburg, M.Fruttiger, et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J. Cell Biol. 2008; 183(3):409-17; PMID:18955553; http://dx.doi.org/10.1083/jcb.200806024
39. N.Inestrosa, G.V.De Ferrari, J.L.Garrido, A.Alvarez, G.H.Olivares, M.I.Barría, M.Bronfman, M.A.Chacón. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem. Int. 2002; 41(5):341-4; PMID:12176076; http://dx.doi.org/10.1016/S0197-0186(02)00056-6
40. N.C.Inestrosa, E.M.Toledo. The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol. Neurodegener. 2008; 3:9; PMID:18652670; http://dx.doi.org/10.1186/1750-1326-3-9
41. F.L'Episcopo, C.Tirolo, N.Testa, S.Caniglia, M.C.Morale, C.Cossetti, P.D'Adamo, E.Zardini, L.Andreoni, A.E.Ihekwaba, et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 2011; 41(2):508-27; http://dx.doi.org/10.1016/j.nbd.2010.10.023
42. F.L'Episcopo, C.Tirolo, S.Caniglia, N.Testa, M.C.Morale, M.F.Serapide, S.Pluchino, B.Marchetti. Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J. Mol. Cell Biol. 2014; 6(1):13-26; http://dx.doi.org/10.1093/jmcb/mjt053
43. T.Duka, V.Duka, J.N.Joyce, A.Sidhu. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 2009; 23(9):2820-30; PMID:19369384; http://dx.doi.org/10.1096/fj.08-120410
44. J.B.J.Kwok, M.Hallupp, C.T.Loy, D.K.Chan, J.Woo, G.D.Mellick, D.D.Buchanan, P.A.Silburn, G.M.Halliday, P.R.Schofield. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005; 58(6):829-39; PMID:16315267; http://dx.doi.org/10.1002/ana.20691
45. S.P.J.Fancy, S.E.Baranzini, C.Zhao, D.I.Yuk, K.A.Irvine, S.Kaing, N.Sanai, R.J.Franklin, D.H.Rowitch. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009; 23(13):1571-85; PMID:19515974; http://dx.doi.org/10.1101/gad.1806309
46. S.Yu, L.Levi, R.Siegel, N.Noy. Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ). J. Biol. Chem. 2012; 287(50):42195-205; PMID:23105114; http://dx.doi.org/10.1074/jbc.M112.410381
47. J.M.Dmetrichuk, R.L.Carlone, G.E.Spencer. Retinoic acid induces neurite outgrowth and growth cone turning in invertebrate neurons. Dev. Biol. 2006; 294(1):39-49; PMID:16626686; http://dx.doi.org/10.1016/j.ydbio.2006.02.018
48. S.Jacobs, D.C.Lie, K.L.DeCicco, Y.Shi, L.M.DeLuca, F.H.Gage, R.M.Evans. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc. Natl. Acad. Sci. U. S. A. 2006; 103(10):3902-7; PMID:16505366; http://dx.doi.org/10.1073/pnas.0511294103
49. M.R.Mizee, D.Wooldrik, K.A.M.Lakeman, B.van het Hof, J.A.Drexhage, D.Geerts, M.Bugiani, E.Aronica, R.E.Mebius, A.Prat, et al. Retinoic acid induces blood-brain barrier development. J. Neurosci. 2013; 33(4):1660-71; PMID:23345238; http://dx.doi.org/10.1523/JNEUROSCI.1338-12.2013
50. E.S.Lippmann, A.Al-Ahmad, S.M.Azarin, S.P.Palecek, E.V.Shusta. A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources. Sci. Rep. 2014; 4:4160; PMID:24561821; http://dx.doi.org/10.1038/srep04160
51. F.J.Jiménez-Jiménez, J.A.Molina, F.de Bustos, M.Ortí-Pareja, J.Benito-León, A.Tallón-Barranco, T.Gasalla, J.Porta, J.Arenas. Serum levels of beta-carotene, alpha-carotene and vitamin A in patients with Alzheimer's disease. Eur. J. Neurol. 1999; 6(4):495-7; http://dx.doi.org/10.1046/j.1468-1331.1999.640495.x
52. M.J.Connor, N.Sidell. Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol. Chem. Neuropathol. 1997; 30(3):239-52; PMID:9165489; http://dx.doi.org/10.1007/BF02815101
53. Y.Ding, A.Qiao, Z.Wang, J.S.Goodwin, E.S.Lee, M.L.Block, M.Allsbrook, M.P.McDonald, G.H.Fan. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 2008; 28(45):11622-34; PMID:18987198; http://dx.doi.org/10.1523/JNEUROSCI.3153-08.2008
54. M.B.Goncalves, E.Clarke, C.Hobbs, T.Malmqvist, R.Deacon, J.Jack, J.P.Corcoran. Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist. Eur. J. Neurosci. 2013; 37(7):1182-92; PMID:23379615; http://dx.doi.org/10.1111/ejn.12142
55. A.Takeda, O.P.Nyssen, A.Syed, E.Jansen, B.Bueno-de-Mesquita, V.Gallo. Vitamin A and carotenoids and the risk of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 2014; 42(1):25-38; PMID:24356061; http://dx.doi.org/10.1159/000355849
56. L.-H.Yin, H.Shen, O.Diaz-Ruiz, C.M.Bäckman, E.Bae, S.J.Yu, Y.Wang. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease. BMC Neurosci. 2012; 13(1):120; PMID:23040108; http://dx.doi.org/10.1186/1471-2202-13-120
57. G.K.Ulusoy, T.Celik, H.Kayir, M.Gürsoy, A.T.Isik, T.I.Uzbay. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res. Bull. 2011; 85(6):380-4; PMID:21600965; http://dx.doi.org/10.1016/j.brainresbull.2011.05.001
58. M.R.Mizee, P.G.Nijland, S.M.A.van der Pol, J.A.Drexhage, B.van Het Hof, R.Mebius, P.van der Valk, J.van Horssen, A.Reijerkerk, H.E.de Vries. Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis. Acta Neuropathol. 2014; 128(5):691-703; PMID:25149081; http://dx.doi.org/10.1007/s00401-014-1335-6
59. S.M.Abtahi Froushani, N.Delirezh, R.Hobbenaghi, G.Mosayebi. Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis. Immunol. Invest. 2014; 43(1):54-68; PMID:24063549; http://dx.doi.org/10.3109/08820139.2013.825269
60. Y.D.Fragoso, P.N.Stoney, P.J.McCaffery. The evidence for a beneficial role of vitamin A in multiple sclerosis. CNS Drugs 2014; 28(4):291-9; PMID:24557746; http://dx.doi.org/10.1007/s40263-014-0148-4
61. J.Massagué. TGF-beta signal transduction. Annu. Rev. Biochem. 1998; 67:753-91; http://dx.doi.org/10.1146/annurev.biochem.67.1.753
62. N.McCormack, S.O'Dea. Regulation of epithelial to mesenchymal transition by bone morphogenetic proteins. Cell. Signal. 2013; 25(12):2856-62; PMID:24044921; http://dx.doi.org/10.1016/j.cellsig.2013.09.012
63. P.Mattar, M.Cayouette. Temporal control of neural progenitors: TGF-β switches the clock forward. Neuron 2014; 84(5):885-8; PMID:25475182; http://dx.doi.org/10.1016/j.neuron.2014.11.013
64. J.Stipursky, D.Francis, R.S.Dezonne, A.P.Bérgamo de Araújo, L.Souza, C.A.Moraes, F.C.Alcantara Gomes. TGF-β1 promotes cerebral cortex radial glia-astrocyte differentiation in vivo. Front. Cell. Neurosci. 2014; 8:393; PMID:25484855; http://dx.doi.org/10.3389/fncel.2014.00393
65. M.A.Perrella, M.K.Jain, M.E.Lee. Role of TGF-beta in vascular development and vascular reactivity. Miner. Electrolyte Metab. 1998; 24(2-3):136-43; PMID:9525696; http://dx.doi.org/10.1159/000057361
66. K.C.Flanders, R.F.Ren, C.F.Lippa. Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol. 1998; 54(1):71-85; PMID:9460794; http://dx.doi.org/10.1016/S0301-0082(97)00066-X
67. S.Dohgu, A.Yamauchi, F.Takata, M.Naito, T.Tsuruo, S.Higuchi, Y.Sawada, Y.Kataoka. Transforming Growth Factor- 1 Upregulates the Tight Junction and P-glycoprotein of Brain Microvascular Endothelial Cells. Cell. Mol. Neurobiol. 2004; 24(3):491-497; PMID:15206827; http://dx.doi.org/10.1023/B:CEMN.0000022776.47302.ce
68. S.Dohgu, F.Takata, A.Yamauchi, S.Nakagawa, T.Egawa, M.Naito, T.Tsuruo, Y.Sawada, M.Niwa, Y.Kataoka. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005; 1038(2):208-15; PMID:15757636; http://dx.doi.org/10.1016/j.brainres.2005.01.027
69. J.H.Seo, T.Maki, M.Maeda, N.Miyamoto, A.C.Liang, K.Hayakawa, L.D.Pham, F.Suwa, A.Taguchi, T.Matsuyama, et al. Oligodendrocyte precursor cells support blood-brain barrier integrity via TGF-β signaling. PLoS One 2014; 9(7):e103174; PMID:25078775; http://dx.doi.org/10.1371/journal.pone.0103174
70. K.C.Flanders, C.F.Lippa, T.W.Smith, D.A.Pollen, M.B.Sporn. Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology 1995; 45(8):1561-9; PMID:7543987; http://dx.doi.org/10.1212/WNL.45.8.1561
71. B.De Servi, C.A.M.La Porta, M.Bontempelli, R.Comolli. Decrease of TGF-β1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp. Gerontol. 2002; 37(6):813-821; PMID:12175481; http://dx.doi.org/10.1016/S0531-5565(02)00018-9
72. I.Tesseur, K.Zou, L.Esposito, F.Bard, E.Berber, J.V.Can, A.H.Lin, L.Crews, P.Tremblay, P.Mathews, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 2006; 116(11):3060-9; PMID:17080199; http://dx.doi.org/10.1172/JCI27341
73. M.Mogi, M.Harada, T.Kondo, H.Narabayashi, P.Riederer, T.Nagatsu. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 1995; 193(2):129-132; PMID:7478158; http://dx.doi.org/10.1016/0304-3940(95)11686-Q
74. L.Qian, S.-J.Wei, D.Zhang, X.Hu, Z.Xu, B.Wilson, J.El-Benna, J.S.Hong, P.M.Flood. Potent Anti-Inflammatory and Neuroprotective Effects of TGF- 1 Are Mediated through the Inhibition of ERK and p47phox-Ser345 Phosphorylation and Translocation in Microglia. J. Immunol. 2008; 181(1):660-668; PMID:18566433; http://dx.doi.org/10.4049/jimmunol.181.1.660
75. F.Nicoletti, R.Di Marco, F.Patti, E.Reggio, A.Nicoletti, P.Zaccone, F.Stivala, P.L.Meroni, A.Reggio. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Clin. Exp. Immunol. 1998; 113(1):96-9; PMID:9697990; http://dx.doi.org/10.1046/j.1365-2249.1998.00604.x
76. M.K.Racke, S.Dhib-Jalbut, B.Cannella, P.S.Albert, C.S.Raine, D.E.McFarlin. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor beta 1. J. Immunol. 1991; 146(9):3012-3017; PMID:1707929
77. A.Liu, L.A.Niswander. Bone morphogenetic protein signalling and vertebrate nervous system development. Nat. Rev. Neurosci. 2005; 6(12):945-54; PMID:16340955; http://dx.doi.org/10.1038/nrn1805
78. Z.Xie, N.Sheng, N.Jing. BMP signaling pathway and spinal cord development. Front. Biol. (Beijing). 2012; 7(1):24-29
79. R.Araya, M.Kudo, M.Kawano, K.Ishii, T.Hashikawa, T.Iwasato, S.Itohara, T.Terasaki, A.Oohira, Y.Mishina, et al. BMP signaling through BMPRIA in astrocytes is essential for proper cerebral angiogenesis and formation of the blood-brain-barrier. Mol. Cell. Neurosci. 2008; 38(3):417-30; PMID:18501628; http://dx.doi.org/10.1016/j.mcn.2008.04.003
80. L.Crews, A.Adame, C.Patrick, A.Delaney, E.Pham, E.Rockenstein, L.Hansen, E.Masliah. Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J. Neurosci. 2010; 30(37):12252-62; PMID:20844121; http://dx.doi.org/10.1523/JNEUROSCI.1305-10.2010
81. D.Li, J.Tang, H.Xu, X.Fan, Y.Bai, L.Yang. Decreased hippocampal cell proliferation correlates with increased expression of BMP4 in the APPswe/PS1DeltaE9 mouse model of Alzheimer's disease. Hippocampus 2008; 18(7):692-8; PMID:18398851; http://dx.doi.org/10.1002/hipo.20428
82. J.Tang, M.Song, Y.Wang, X.Fan, H.Xu, Y.Bai. Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2009; 385(3):341-5; PMID:19463786; http://dx.doi.org/10.1016/j.bbrc.2009.05.067
83. B.K.Harvey, A.Mark, J.Chou, G.J.Chen, B.J.Hoffer, Y.Wang. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease. Brain Res. 2004; 1022(1-2):88-95; PMID:15353217; http://dx.doi.org/10.1016/j.brainres.2004.06.072
84. N.D.Stull, J.W.Jung, L.Iacovitti. Induction of a dopaminergic phenotype in cultured striatal neurons by bone morphogenetic proteins. Dev. Brain Res. 2001; 130(1):91-98; http://dx.doi.org/10.1016/S0165-3806(01)00216-4
85. A.Brederlau. Bone Morphogenetic Proteins but Not Growth Differentiation Factors Induce Dopaminergic Differentiation in Mesencephalic Precursors. Mol. Cell. Neurosci. 2002; 21(3):367-378; PMID:12498780; http://dx.doi.org/10.1006/mcne.2002.1178
86. J.Ara, J.See, P.Mamontov, A.Hahn, P.Bannerman, D.Pleasure, J.B.Grinspan. Bone morphogenetic proteins 4, 6, and 7 are up-regulated in mouse spinal cord during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2008; 86(1):125-35; PMID:17722066; http://dx.doi.org/10.1002/jnr.21462
87. M.Deininger, R.Meyermann, H.Schluesener. Detection of two transforming growth factor-beta-related morphogens, bone morphogenetic proteins-4 and -5, in RNA of multiple sclerosis and Creutzfeldt-Jakob disease lesions. Acta Neuropathol. 1995; 90(1):76-9; PMID:7572083; http://dx.doi.org/10.1007/BF00294462
88. J.K.Sabo, T.D.Aumann, D.Merlo, T.J.Kilpatrick, H.S.Cate. Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions. J. Neurosci. 2011; 31(12):4504-10; PMID:21430151; http://dx.doi.org/10.1523/JNEUROSCI.5859-10.2011
89. C.Suri, P.F.Jones, S.Patan, S.Bartunkova, P.C.Maisonpierre, S.Davis, T.N.Sato, G.D.Yancopoulos. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87(7):1171-80; PMID:8980224; http://dx.doi.org/10.1016/S0092-8674(00)81813-9
90. P.C.Maisonpierre, C.Suri, P.F.Jones, S.Bartunkova, S.J.Wiegand, C.Radziejewski, D.Compton, J.McClain, T.H.Aldrich, N.Papadopoulos, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277(5322):55-60; PMID:9204896; http://dx.doi.org/10.1126/science.277.5322.55
91. H.J.Lee, C.-H.Cho, S.-J.Hwang, H.H.Choi, K.T.Kim, S.Y.Ahn, J.H.Kim, J.L.Oh, G.M.Lee, G.Y.Koh. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J. 2004; 18(11):1200-8; PMID:15284220; http://dx.doi.org/10.1096/fj.03-1466com
92. Z.Meng, M.Li, Q.He, S.Jiang, X.Zhang, J.Xiao, Y.Bai. Ectopic expression of human angiopoietin-1 promotes functional recovery and neurogenesis after focal cerebral ischemia. Neuroscience 2014; 267:135-46; PMID:24607344; http://dx.doi.org/10.1016/j.neuroscience.2014.02.036
93. L.Marteau, E.Pacary, S.Valable, M.Bernaudin, F.Guillemot, E.Petit. Angiopoietin-2 regulates cortical neurogenesis in the developing telencephalon. Cereb. Cortex 2011; 21(7):1695-702; http://dx.doi.org/10.1093/cercor/bhq243
94. G.Thurston. Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1. Science (80-.). 1999; 286(5449):2511-2514; http://dx.doi.org/10.1126/science.286.5449.2511
95. G.Thurston, J.S.Rudge, E.Ioffe, H.Zhou, L.Ross, S.D.Croll, N.Glazer, J.Holash, D.M.McDonald, G.D.Yancopoulos. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 2000; 6(4):460-3; PMID:10742156; http://dx.doi.org/10.1038/74725
96. Z.G.Zhang, L.Zhang, W.Tsang, H.Soltanian-Zadeh, D.Morris, R.Zhang, A.Goussev, C.Powers, T.Yeich, M.Chopp. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2002; 22(4):379-92; PMID:11919509; http://dx.doi.org/10.1097/00004647-200204000-00002
97. N.Nourhaghighi, K.Teichert-Kuliszewska, J.Davis, D.J.Stewart, S.Nag. Altered Expression of Angiopoietins During Blood-Brain Barrier Breakdown and Angiogenesis. Lab. Investig. 2003; 83(8):1211-1222; http://dx.doi.org/10.1097/01.LAB.0000082383.40635.FE
98. H.Yu, P.Wang, P.An, Y.Xue, X.Yixue. Recombinant human angiopoietin-1 ameliorates the expressions of ZO-1, occludin, VE-cadherin, and PKCα signaling after focal cerebral ischemia/reperfusion in rats. J. Mol. Neurosci. 2012; 46(1):236-47; PMID:21710361; http://dx.doi.org/10.1007/s12031-011-9584-5
99. Y.Zhao, Z.Li, R.Wang, J.Wei, G.Li, H.Zhao. Angiopoietin 1 counteracts vascular endothelial growth factor-induced blood-brain barrier permeability and alleviates ischemic injury in the early stages of transient focal cerebral ischemia in rats. Neurol. Res. 2010; 32(7):748-55; PMID:19660197; http://dx.doi.org/10.1179/016164109X12445616596562
100. H.K.Avraham, S.Jiang, Y.Fu, H.Nakshatri, H.Ovadia, S.Avraham. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J. Pathol. 2014; 232(3):369-81; PMID:24421076; http://dx.doi.org/10.1002/path.4304
101. D.-M.Lai, H.Li, C.-C.Lee, Y.S.Tzeng, Y.H.Hsieh, W.M.Hsu, F.J.Hsieh, J.T.Cheng, Y.K.Tu. Angiopoietin-like protein 1 decreases blood brain barrier damage and edema following focal cerebral ischemia in mice. Neurochem. Int. 2008; 52(3):470-7; PMID:17919782; http://dx.doi.org/10.1016/j.neuint.2007.08.010
102. C.Bouleti, T.Mathivet, B.Coqueran, J.M.Serfaty, M.Lesage, E.Berland, C.Ardidie-Robouant, G.Kauffenstein, D.Henrion, B.Lapergue, et al. Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur. Heart J. 2013; 34(47):3657-68; PMID:23674618; http://dx.doi.org/10.1093/eurheartj/eht153
103. L.Thirumangalakudi, P.G.Samany, A.Owoso, B.Wiskar, P.Grammas. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J. Alzheimers. Dis. 2006; 10(1):111-8; PMID:16988487
104. D.Paris, K.Townsend, A.Quadros, J.Humphrey, J.Sun, S.Brem, M.Wotoczek-Obadia, A.DelleDonne, N.Patel, D.F.Obregon, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis 2004; 7(1):75-85; PMID:15302999; http://dx.doi.org/10.1023/B:AGEN.0000037335.17717.bf
105. A.Sillén, J.Brohede, L.Lilius, C.Forsell, J.Andrade, J.Odeberg, H.Ebise, B.Winblad, C.Graff. Linkage to 20p13 including the ANGPT4 gene in families with mixed Alzheimer's disease and vascular dementia. J. Hum. Genet. 2010; 55(10):649-55; http://dx.doi.org/10.1038/jhg.2010.79
106. H.Jiang, F.Zhang, J.Yang, S.Han. Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis. Exp. Neurol. 2014; 261:245-57; PMID:24852101; http://dx.doi.org/10.1016/j.expneurol.2014.05.013
107. Y.Luo, D.Raible, J.A.Raper. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993; 75(2):217-27; PMID:8402908; http://dx.doi.org/10.1016/0092-8674(93)80064-L
108. Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee. Cell 1999; 97(5):551-2; PMID:10367884; http://dx.doi.org/10.1016/S0092-8674(00)80766-7
109. L.Tamagnone, S.Artigiani, H.Chen, Z.He, G.I.Ming, H.Song, A.Chedotal, M.L.Winberg, C.S.Goodman, M.Poo, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999; 99(1):71-80; PMID:10520995; http://dx.doi.org/10.1016/S0092-8674(00)80063-X
110. Z.He, M.Tessier-Lavigne. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997; 90(4):739-51; PMID:9288753; http://dx.doi.org/10.1016/S0092-8674(00)80534-6
111. Koncina E, Roth L, Gonthier B, Bagnard D. Role of Semaphorins during Axon Growth and Guidance. Adv Exp Med Biol 621:50-64
112. D.Bagnard, M.Lohrum, D.Uziel, A.W.Püschel, J.Bolz. Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development 1998; 125(24):5043-53; PMID:9811588
113. F.De Castro, L.Hu, H.Drabkin, C.Sotelo, A.Chédotal. Chemoattraction and chemorepulsion of olfactory bulb axons by different secreted semaphorins. J. Neurosci. 1999; 19(11):4428-36; PMID:10341244
114. G.Serini, D.Valdembri, S.Zanivan, G.Morterra, C.Burkhardt, F.Caccavari, L.Zammataro, L.Primo, L.Tamagnone, M.Logan, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424(6947):391-7; PMID:12879061; http://dx.doi.org/10.1038/nature01784
115. K.Suzuki, A.Kumanogoh, H.Kikutani. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 2008; 9(1):17-23; PMID:18087252; http://dx.doi.org/10.1038/ni1553
116. L.M.Acevedo, S.Barillas, S.M.Weis, J.R.Göthert, D.A.Cheresh. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008; 111(5):2674-80; PMID:18180379; http://dx.doi.org/10.1182/blood-2007-08-110205
117. A.Le Guelte, E.-M.Galan-Moya, J.Dwyer, L.Treps, G.Kettler, J.K.Hebda, S.Dubois, C.Auffray, H.Chneiweiss, N.Bidere, et al. Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J. Cell Sci. 2012; 125(Pt 17):4137-46; PMID:22685328; http://dx.doi.org/10.1242/jcs.108282
118. E.S.Smith, A.Jonason, C.Reilly, J.Veeraraghavan, T.Fisher, M.Doherty, E.Klimatcheva, C.Mallow, C.Cornelius, J.E.Leonard, et al. SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol. Dis. 2015; 73:254-268; http://dx.doi.org/10.1016/j.nbd.2014.10.008
119. P.F.Good, D.Alapat, A.Hsu, C.Chu, D.Perl, X.Wen, D.E.Burstein, D.S.Kohtz. A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J. Neurochem. 2004; 91(3):716-36; PMID:15485501; http://dx.doi.org/10.1111/j.1471-4159.2004.02766.x
120. G.Jun, H.Asai, E.Zeldich, E.Drapeau, C.Chen, J.Chung, J.H.Park, S.Kim, V.Haroutunian, T.Foroud, et al. PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann. Neurol. 2014; 76(3):379-92; PMID:25043464; http://dx.doi.org/10.1002/ana.24219
121. J.Clarimon, S.Scholz, H.-C.Fung, J.Hardy, J.Eerola, O.Hellstrom, C.M.Chen, Y.R.Wu, P.J.Tienari, A.Singleton. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am. J. Hum. Genet. 2006; 78(6):1082-4; author reply 1092-4; PMID:16685660; http://dx.doi.org/10.1086/504727
122. T.Okuno, Y.Nakatsuji, A.Kumanogoh. The role of immune semaphorins in multiple sclerosis. FEBS Lett. 2011; 585(23):3829-35; PMID:21420960; http://dx.doi.org/10.1016/j.febslet.2011.03.033
123. W.M.Pardridge. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 2006; 6(5):494-500; PMID:16839816; http://dx.doi.org/10.1016/j.coph.2006.06.001
124. H.Peluffo, U.Unzueta, M.L.Negro-Demontel, Z.Xu, E.Váquez, N.Ferrer-Miralles, A.Villaverde. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol. Adv. 33(2):277-87; PMID:25698504; http://dx.doi.org/10.1016/j.biotechadv.2015.02.004
125. A.L.Southwell, S.Franciosi, E.B.Villanueva, Y.Xie, L.A.Winter, J.Veeraraghavan, A.Jonason, B.Felczak, W.Zhang, V.Kovalik, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2015; 76:46-56; PMID:25662335; http://dx.doi.org/10.1016/j.nbd.2015.01.002
126. R.Derynck, Y.E.Zhang. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425(6958):577-84; PMID:14534577; http://dx.doi.org/10.1038/nature02006
127. V.Pendaries, F.Verrecchia, S.Michel, A.Mauviel. Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner. Oncogene 2003; 22(50):8212-20; PMID:14603262; http://dx.doi.org/10.1038/sj.onc.1206913
128. N.Sheng, Z.Xie, C.Wang, G.Bai, K.Zhang, Q.Zhu, J.Song, F.Guillemot, Y.G.Chen, A.Lin, et al. Retinoic acid regulates bone morphogenic protein signal duration by promoting the degradation of phosphorylated Smad1. Proc. Natl. Acad. Sci. U. S. A. 2010; 107(44):18886-91; PMID:20956305; http://dx.doi.org/10.1073/pnas.1009244107
129. X.Guo, X.-F.Wang. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009; 19(1):71-88; PMID:19002158; http://dx.doi.org/10.1038/cr.2008.302
130. W.Kim, S.-O.Moon, S.Y.Lee, K.Y.Jang, C.H.Cho, G.Y.Koh, K.S.Choi, K.H.Yoon, M.J.Sung, D.H.Kim, et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J. Am. Soc. Nephrol. 2006; 17(9):2474-83; PMID:16885409; http://dx.doi.org/10.1681/ASN.2006020109
131. W.Kim. The role of angiopoietin-1 in kidney disease. Electrolyte Blood Press. 2008; 6(1):22-6.
132. T.Nakamura, T.Okada, M.Endo, T.Kadomatsu, T.Taniwaki, A.Sei, H.Odagiri, T.Masuda, T.Fujimoto, T.Nakamura, et al. Angiopoietin-like protein 2 induced by mechanical stress accelerates degeneration and hypertrophy of the ligamentum flavum in lumbar spinal canal stenosis. PLoS One 2014; 9(1):e85542; PMID:24465594; http://dx.doi.org/10.1371/journal.pone.0085542
133. Y.Glinka, G.J.Prud'homme. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J. Leukoc. Biol. 2008; 84(1):302-10; PMID:18436584; http://dx.doi.org/10.1189/jlb.0208090
134. Y.Cao, A.Szabolcs, S.K.Dutta, U.Yaqoob, K.Jagavelu, L.Wang, E.B.Leof, R.A.Urrutia, V.H.Shah, D.Mukhopadhyay. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J. Biol. Chem. 2010; 285(41):31840-8; PMID:20675371; http://dx.doi.org/10.1074/jbc.M110.151696
135. Y.E.Zhang. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009; 19(1):128-39; PMID:19114990; http://dx.doi.org/10.1038/cr.2008.328
136. A.Yen, M.S.Roberson, S.Varvayanis, A.T.Lee. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res. 1998; 58(14):3163-72; PMID:9679985
137. R.K.Bikkavilli, C.C.Malbon. Mitogen-activated protein kinases and Wnt/beta-catenin signaling: Molecular conversations among signaling pathways. Commun. Integr. Biol. 2009; 2(1):46-9; PMID:19513264; http://dx.doi.org/10.4161/cib.2.1.7503
138. D.Guardavaccaro, H.Clevers. Wnt/β-catenin and MAPK signaling: allies and enemies in different battlefields. Sci. Signal. 2012; 5(219):pe15; PMID:22494969; http://dx.doi.org/10.1126/scisignal.2002921
139. D.Elia, D.Madhala, E.Ardon, R.Reshef, O.Halevy. Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: Involvement of MAPK/ERK and PI3K/Akt pathways. Biochim. Biophys. Acta 2007; 1773(9):1438-46
140. N.Kessaris, F.Jamen, L.L.Rubin, W.D.Richardson. Cooperation between sonic hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical precursors. Development 2004; 131(6):1289-98; PMID:14960493; http://dx.doi.org/10.1242/dev.01027
141. W.-H.Zhu, A.MacIntyre, R.F.Nicosia. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am. J. Pathol. 2002; 161(3):823-30; PMID:12213710; http://dx.doi.org/10.1016/S0002-9440(10)64242-3
142. A.Hashiramoto, C.Sakai, K.Yoshida, K.Tsumiyama, Y.Miura, K.Shiozawa, M.Nose, K.Komai, S.Shiozawa. Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt. Arthritis Rheum. 2007; 56(7):2170-9; PMID:17599743; http://dx.doi.org/10.1002/art.22727
143. Y.Li, J.Chen, C.Wu, L.Wang, M.Lu, X.Chen. Hepatitis B virus/hepatitis C virus upregulate angiopoietin-2 expression through mitogen-activated protein kinase pathway. Hepatol. Res. 2010; 40(10):1022-33; PMID:20887338; http://dx.doi.org/10.1111/j.1872-034X.2010.00712.x
144. D.-K.He, Y.-R.Shao, L.Zhang, J.Shen, Z.Y.Zhong, J.Wang, G.Xu. Adenovirus-delivered angiopoietin-1 suppresses NF-κB and p38 MAPK and attenuates inflammatory responses in phosgene-induced acute lung injury. Inhal. Toxicol. 2014; 26(3):185-92; PMID:24517841; http://dx.doi.org/10.3109/08958378.2013.872213
145. J.Aurandt, W.Li, K.-L.Guan. Semaphorin 4D activates the MAPK pathway downstream of plexin-B1. Biochem. J. 2006; 394(Pt 2):459-64; PMID:16187944; http://dx.doi.org/10.1042/BJ20051123
146. R.J.Pasterkamp, J.J.Peschon, M.K.Spriggs, A.L.Kolodkin. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003; 424(6947):398-405; PMID:12879062; http://dx.doi.org/10.1038/nature01790
147. G.López-Carballo, L.Moreno, S.Masiá, P.Pérez, D.Barettino. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 2002; 277(28):25297-304; http://dx.doi.org/10.1074/jbc.M201869200
148. E.Ohashi, T.Kogai, H.Kagechika, G.A.Brent. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res. 2009; 69(8):3443-50; PMID:19351850; http://dx.doi.org/10.1158/0008-5472.CAN-08-3234
149. C.Roolf, S.Krohn, C.Kretzschmar, et al. PI3K/Akt Signaling Interacts With Wnt/β-Catenin Signaling But Does Not Induce An Accumulation Of β-Catenin In The Nucleus Of Acute Lymphoblastic Leukemia Cell Lines. Blood 2013; 122(21):4886
150. N.A.Riobó, K.Lu, X.Ai, G.M.Haines, C.P.Emerson. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U. S. A. 2006; 103(12):4505-10; http://dx.doi.org/10.1073/pnas.0504337103
151. I.Kim, H.G.Kim, J.N.So, J.H.Kim, H.J.Kwak, G.Y.Koh. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ. Res. 86(1):24-9; PMID:10625301; http://dx.doi.org/10.1161/01.RES.86.1.24
152. H.T.Yuan, E.V.Khankin, S.A.Karumanchi, S.M.Parikh. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol. Cell. Biol. 2009; 29(8):2011-22; PMID:19223473; http://dx.doi.org/10.1128/MCB.01472-08
153. R.J.Pasterkamp. Semaphorins: receptor and intracellular mechanisms. Adv. Exp. Med. Biol. 2007; 600:38-51; PMID:17607945; http://dx.doi.org/10.1007/978-0-387-70956-7